| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/09/2005 | WO2005082379A1 Myocardial perfusion imaging using adenosine receptor agonists |
| 09/09/2005 | WO2005082338A2 Prodrugs for the intravenous administration of proton pump inhibitors |
| 09/09/2005 | WO2005082337A2 Compositions comprising prodrugs of proton pump inhibitors |
| 09/09/2005 | WO2005082336A2 Kit comprising a plaster that optionally contains an active ingredient and an agent that prevents skin irritation |
| 09/09/2005 | WO2005082335A1 Ophthalmic preparation |
| 09/09/2005 | WO2005082334A1 Sustained-release cream preparation |
| 09/09/2005 | WO2005082333A1 Alginate viscoelastic composition, method of use and package |
| 09/09/2005 | WO2005082332A2 Dissolvable film comprising an active ingredient and method of manufacture |
| 09/09/2005 | WO2005082048A2 Dissolvable film and method of manufacture |
| 09/09/2005 | WO2005082023A2 Heterocyclic self-immolative linkers and conjugates |
| 09/09/2005 | WO2005081711A2 Monomethylvaline compounds capable of conjugation to ligands |
| 09/09/2005 | WO2005062947A3 Methods and compositions for identifying rna-binding proteins |
| 09/09/2005 | WO2005027979A3 Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells |
| 09/09/2005 | WO2005023217A3 Granular sustained release preparation and production thereof |
| 09/09/2005 | WO2005023175B1 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 09/09/2005 | WO2005016262A3 Methods for administering aripiprazole |
| 09/09/2005 | WO2005007122A3 Polymer stabilization |
| 09/09/2005 | WO2004096998A3 Nanoparticular tumor targeting and therapy |
| 09/09/2005 | WO2004080371A3 Injectable isotonic solution of gatifloxacin pre-diluted in glucose. |
| 09/09/2005 | WO2004075824A8 Pharmaceutical compositions for nasal delivery |
| 09/09/2005 | WO2004064777A3 Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer |
| 09/09/2005 | WO2004046169A8 Activation of peptide prodrugs by hk2 |
| 09/09/2005 | WO2003086284A3 Colon tumor specific binding peptides |
| 09/09/2005 | CA2841741A1 Monomethylvaline compounds capable of conjugation to ligands |
| 09/09/2005 | CA2691611A1 Myocardial perfusion imaging using adenosine receptor agonists |
| 09/09/2005 | CA2557471A1 Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors |
| 09/09/2005 | CA2557397A1 Protein drug sustained-release microparticle preparation for injection and process for producing the same |
| 09/09/2005 | CA2557323A1 Alginate viscoelastic composition, method of use and package |
| 09/09/2005 | CA2556832A1 Binding peptidomimetics and uses of the same |
| 09/09/2005 | CA2556756A1 Compositions comprising prodrugs of proton pump inhibitors |
| 09/09/2005 | CA2556752A1 Heterocyclic self-immolative linkers and conjugates |
| 09/09/2005 | CA2556114A1 Method for the production of hyperbranched polysaccharide fractions |
| 09/09/2005 | CA2555179A1 Method for preparing adjustably bioresorbable sol-gel derived sio2 |
| 09/09/2005 | CA2554908A1 Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration |
| 09/09/2005 | CA2554870A1 Long-acting solid formulation comprising triptorelin acetate |
| 09/09/2005 | CA2548771A1 A medical solution, a method for producing said medical solution and use thereof |
| 09/09/2005 | CA2543888A1 Monomethylvaline compounds capable of conjugation to ligands |
| 09/08/2005 | US20050197434 Granulate or powder for producing coating or binding agents for medicaments |
| 09/08/2005 | US20050197401 Growth factor-binding compounds and methods of use |
| 09/08/2005 | US20050197392 O-desmethylvenlafaxine and methods of preparing and using the same |
| 09/08/2005 | US20050197319 Allergen inactivating agent |
| 09/08/2005 | US20050197316 Method of enhancing drainage of lacrimal system with purinergic receptor agonists |
| 09/08/2005 | US20050197308 drug delivery devices having skin piercing segments comprising solid biodegradable reservoirs containing antigens |
| 09/08/2005 | US20050197302 Organic amine salt of closantel; administered with carrier and optionally macrocyclic lactone; bioavailability, blood concentration; veterinary medicine |
| 09/08/2005 | US20050197297 Method for increasing the serum half-life of a biologically active molecule |
| 09/08/2005 | US20050197296 Agents for preventing and treating thrombocytopenia |
| 09/08/2005 | US20050197295 Modified annexin proteins and methods for preventing thrombosis |
| 09/08/2005 | US20050197282 Compositions and methods for treatment of psoriasis |
| 09/08/2005 | US20050196793 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 09/08/2005 | US20050196791 Probe for mass spectrometry |
| 09/08/2005 | US20050196767 siNA molecule comprising a double-stranded structure that down-regulates expression of GAB2 (Growth factor receptor-bound protein 2 (GRB2) , where the siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 09/08/2005 | US20050196457 Controlling particle size distribution; preparing a quench liquid;pumping the first phase and the second phase through manifold that includes a plurality of static mixers to form an emulsion; polydispersity |
| 09/08/2005 | US20050196456 Controlled release particles |
| 09/08/2005 | US20050196450 Administering ethyl and/or isopropyl alcohol to burns and surrounding tissues; may contain ammonium hydroxide and/or bicarbonate; reducing level of cytokine, interleukin, and/or tumor necrosis factor; wound healing agents |
| 09/08/2005 | US20050196443 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 09/08/2005 | US20050196435 Encapsulating drug; drug delivery |
| 09/08/2005 | US20050196428 Dilute aqueous solution containing epidermal growth factor in gel |
| 09/08/2005 | US20050196417 Taste masking complex of antihistamine and alginate |
| 09/08/2005 | US20050196401 Energy-activated targeted cancer therapy |
| 09/08/2005 | US20050196399 antibody capable of specifically recognizing two regions of the A4 peptide/A beta 4, wherein the first region comprises the amino acid sequence AEFRHDSGY and the second region comprises the amino acid sequence YEVHHQKLVFFAEDVG |
| 09/08/2005 | US20050196393 Add trisodium citrate to get cryoprecipitate without freezing plasma, without chromatography; single donors, limited pools; cryoprecipitate formed into a fibrin fabric; surgeries, wounds |
| 09/08/2005 | US20050196391 Method and composition for inhibiting cancer cell growth |
| 09/08/2005 | US20050196378 G-CSF conjugates |
| 09/08/2005 | US20050196375 Slow release drug delivery systems; infection resistance; tissue and blood compatability; medicant distributed throughout polymer and reversibly associated |
| 09/08/2005 | US20050196365 Method for improving sensory characteristics of semisolid predominantly anhydrous lipids |
| 09/08/2005 | US20050196346 Micronized or spray dried solid active ingredient (oxitropium or tiotropium salts which are soluble in water), and coating consisting of fatty acid, alcohol derivative, and poloxamer |
| 09/08/2005 | US20050195943 Method of forming subtraction images |
| 09/07/2005 | EP1571212A1 Recombinat protein containing albumin multimer |
| 09/07/2005 | EP1570862A1 Highly soluble binary cyclodextrin inclusion complexes |
| 09/07/2005 | EP1570850A1 Topical formulations for treatment of rosacea |
| 09/07/2005 | EP1570849A1 Freeze-dried preparation of stabilized anthracycline compound |
| 09/07/2005 | EP1570270A2 Therapeutic bioconjugates |
| 09/07/2005 | EP1570262A1 Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition |
| 09/07/2005 | EP1570067A2 Methods and compositions for immunization against hiv |
| 09/07/2005 | EP1569724A1 Formulations containing melatonin, ginkgo biloba, and biotin |
| 09/07/2005 | EP1569694A1 Polyamine conjugates with acidic retinoids and preparation thereof |
| 09/07/2005 | EP1569693A1 Pharmaceutical compositions having a modified vehicle |
| 09/07/2005 | EP1569691A2 Delivery of pharmaceutical agents via the human insulin receptor |
| 09/07/2005 | EP1569690A1 Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent |
| 09/07/2005 | EP1569683A2 Modified natriuretic compounds, conjugates, and uses thereof |
| 09/07/2005 | EP1569681A1 Freeze-dried interferon-gammad; composition for transpulmonary administration and inhalation system therefor |
| 09/07/2005 | EP1569678A2 Peptides which target tumor and endothelial cells, compositions and uses thereof |
| 09/07/2005 | EP1569676A2 Calcitonin drug-oligomer conjugates, and uses thereof |
| 09/07/2005 | EP1569665A2 Composition and method for mammary disinfection during winter conditions |
| 09/07/2005 | EP1569664A2 Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them |
| 09/07/2005 | EP1569663A2 Ifosfamide compositions for parenteral administration and a process for their preparation |
| 09/07/2005 | EP1569629A1 Topical antiinflammatory preparations of g(g)-terpinene |
| 09/07/2005 | EP1569624A2 Density-controlled particulate suspensions for foodstuff, cosmetic, pharmaceutical and other uses |
| 09/07/2005 | EP1569623A1 A topical nanoparticulate spironolactone formulation |
| 09/07/2005 | EP1569619A1 Ph triggered targeted controlled release systems |
| 09/07/2005 | EP1569616A2 An exopolysaccharides delivery system for active molecules |
| 09/07/2005 | EP1455760B1 Ultrapure oral fludara formulation with a fast releasing active substance |
| 09/07/2005 | EP1439829B1 Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient |
| 09/07/2005 | EP1379223A4 Dental formulation |
| 09/07/2005 | EP1368062B1 Gel for the treatment of cats and dogs |
| 09/07/2005 | EP1294369B1 NOVEL FORMULATIONS OF $g(a)-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE |
| 09/07/2005 | EP1196195B1 Use of a fatty acid derivate in nasogastric enteral formulations |
| 09/07/2005 | EP1191925B1 Sustained release dosage form unit having latex coating and method of making the same |
| 09/07/2005 | EP1140026B1 Biodegradble polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 09/07/2005 | EP1140016B1 Composition set and kit for use in intraocular surgery |